Last reviewed · How we verify
erythropoetin beta
Erythropoetin beta, developed by Charite University in Berlin, Germany, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-term revenue generation potential. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | erythropoetin beta |
|---|---|
| Also known as | NeoRecormom 10.000 I.E. Patronen Zul.Nr. EU/1/97/031/021-022 |
| Sponsor | Charite University, Berlin, Germany |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Vafseo Outcomes In-Center Experience (PHASE3)
- Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy (PHASE3)
- A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India (PHASE4)
- Correction of Anaemia and Progression of Renal Failure on Transplanted Patients (PHASE4)
- A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA. (PHASE3)
- A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia. (PHASE3)
- Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- erythropoetin beta CI brief — competitive landscape report
- erythropoetin beta updates RSS · CI watch RSS
- Charite University, Berlin, Germany portfolio CI